Follow
Josep M Llovet
Josep M Llovet
Prof. of Medicine - Director M Sinai Liver Cancer Prog/ Prof of Research ICREA, BCLC group
Verified email at clinic.cat - Homepage
Title
Cited by
Cited by
Year
Sorafenib in advanced hepatocellular carcinoma
JM Llovet, S Ricci, V Mazzaferro, P Hilgard, E Gane, JF Blanc, ...
New England journal of medicine 359 (4), 378-390, 2008
148512008
EASL clinical practice guidelines: management of hepatocellular carcinoma
PR Galle, A Forner, JM Llovet, V Mazzaferro, F Piscaglia, JL Raoul, ...
Journal of hepatology 69 (1), 182-236, 2018
61582018
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference
J Bruix, M Sherman, JM Llovet, M Beaugrand, R Lencioni, AK Burroughs, ...
Journal of hepatology 35 (3), 421-430, 2001
51362001
Prognosis of hepatocellular carcinoma: the BCLC staging classification
JM Llovet, C Brú, J Bruix
Seminars in liver disease 19 (03), 329-338, 1999
44571999
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma
R Lencioni, JM Llovet
Seminars in liver disease 30 (01), 052-060, 2010
41242010
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
JM Llovet, MI Real, X Montaña, R Planas, S Coll, J Aponte, C Ayuso, ...
The Lancet 359 (9319), 1734-1739, 2002
38482002
Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival
JM Llovet, J Bruix
Hepatology 37 (2), 429-442, 2003
37912003
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
J Bruix, S Qin, P Merle, A Granito, YH Huang, G Bodoky, M Pracht, ...
The Lancet 389 (10064), 56-66, 2017
34572017
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
V Mazzaferro, JM Llovet, R Miceli, S Bhoori, M Schiavo, L Mariani, ...
The lancet oncology 10 (1), 35-43, 2009
21572009
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ...
The Lancet 389 (10064), 67-76, 2017
20662017
Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation
JM Llovet, J Fuster, J Bruix
Hepatology 30 (6), 1434-1440, 1999
20451999
Design and endpoints of clinical trials in hepatocellular carcinoma
JM Llovet, AM Di Bisceglie, J Bruix, BS Kramer, R Lencioni, AX Zhu, ...
Journal of the National Cancer Institute 100 (10), 698-711, 2008
20422008
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
SM Wilhelm, L Adnane, P Newell, A Villanueva, JM Llovet, M Lynch
Molecular cancer therapeutics 7 (10), 3129-3140, 2008
16432008
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
K Schulze, S Imbeaud, E Letouzé, LB Alexandrov, J Calderaro, ...
Nature genetics 47 (5), 505-511, 2015
16352015
EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma
EO for Research, European Association for the Study of the Liver
Journal of hepatology 56 (4), 908-943, 2012
15722012
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
J Bridgewater, PR Galle, SA Khan, JM Llovet, JW Park, T Patel, TM Pawlik, ...
Journal of hepatology 60 (6), 1268-1289, 2014
15562014
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model
X Forns, S Ampurdanes, JM Llovet, J Aponte, L Quintó, E Martınez-Bauer, ...
Hepatology 36 (4), 986-992, 2002
15312002
Molecular therapies and precision medicine for hepatocellular carcinoma
JM Llovet, R Montal, D Sia, RS Finn
Nature reviews Clinical oncology 15 (10), 599-616, 2018
15182018
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo …
AX Zhu, YK Kang, CJ Yen, RS Finn, PR Galle, JM Llovet, E Assenat, ...
The lancet oncology 20 (2), 282-296, 2019
14752019
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials
JM Llovet, J Bustamante, A Castells, R Vilana, MDC Ayuso, M Sala, C Brú, ...
Hepatology 29 (1), 62-67, 1999
14641999
The system can't perform the operation now. Try again later.
Articles 1–20